Traders Buy Large Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of unusually large options trading activity on Tuesday. Traders acquired 33,848 call options on the company. This represents an increase of approximately 52% compared to the typical daily volume of 22,258 call options.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the sale, the chief executive officer now owns 87,125 shares in the company, valued at $1,145,693.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the transaction, the vice president now directly owns 1 shares of the company’s stock, valued at $13.05. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the transaction, the chief executive officer now directly owns 87,125 shares of the company’s stock, valued at $1,145,693.75. The disclosure for this sale can be found here. Insiders have sold 390,738 shares of company stock worth $5,132,766 over the last 90 days. Corporate insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently modified their holdings of the stock. Asset Management One Co. Ltd. increased its stake in Teva Pharmaceutical Industries by 5.6% during the 3rd quarter. Asset Management One Co. Ltd. now owns 650,151 shares of the company’s stock worth $6,632,000 after purchasing an additional 34,395 shares in the last quarter. Bfsg LLC acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $159,000. Commonwealth Equity Services LLC boosted its position in Teva Pharmaceutical Industries by 5.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 255,477 shares of the company’s stock worth $2,606,000 after acquiring an additional 12,587 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in shares of Teva Pharmaceutical Industries by 5.6% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 351,170 shares of the company’s stock valued at $3,582,000 after buying an additional 18,519 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,902,235 shares of the company’s stock valued at $19,403,000 after buying an additional 19,906 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $14.03 on Wednesday. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. The stock has a market cap of $15.73 billion, a PE ratio of -29.85, a price-to-earnings-growth ratio of 1.65 and a beta of 1.05. The stock has a 50-day moving average of $13.55 and a 200-day moving average of $11.50. Teva Pharmaceutical Industries has a one year low of $7.09 and a one year high of $14.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. The company had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. As a group, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several research reports. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Monday, February 5th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and upped their target price for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Finally, Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their target price for the company from $12.00 to $19.00 in a research report on Monday, February 12th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.